4.6 Article

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

期刊

NATURE BIOMEDICAL ENGINEERING
卷 5, 期 8, 页码 815-829

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41551-021-00718-9

关键词

-

资金

  1. NIH [NCATS 1-UG3-HL-141797-01, NCATS 1-UH3-HL-141797-01]
  2. DARPA [W911NF-12-2-0036, W911NF-16-C-0050]
  3. Bill and Melinda Gates Foundation
  4. Marc Haas Foundation
  5. Wyss Institute for Biologically Inspired Engineering at Harvard University

向作者/读者索取更多资源

The microfluidic bronchial-airway-on-a-chip model, lined with human bronchial-airway epithelium and pulmonary endothelium, can replicate viral infections, cytokine production, and immune cell recruiting, facilitating the rapid identification of antiviral therapeutics and prophylactics with repurposing potential. A variety of drug combinations and treatments were tested on the chip to demonstrate their efficacy in combating infections and the potential for repurposing.
A microfluidic bronchial-airway-on-a-chip lined by human bronchial-airway epithelium and pulmonary endothelium can be used to rapidly identify antiviral therapeutics and prophylactics with repurposing potential. The rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells. In airway chips infected with influenza A, the co-administration of nafamostat with oseltamivir doubled the treatment-time window for oseltamivir. In chips infected with pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据